Details of the Drug Combination

General Information of Drug Combination (ID: DCO26JX)

Drug Combination Name
CA4P JQ1
Indication
Disease Entry Status REF
Diffuse intrinsic pontine glioma Investigative [1]
Component Drugs CA4P   DM9R0ZL JQ1   DM3XQDH
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SU-DIPG-XIII
Zero Interaction Potency (ZIP) Score: 12.468
Bliss Independence Score: 16.085
Loewe Additivity Score: 2.249
LHighest Single Agent (HSA) Score: 10.908

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CA4P
Disease Entry ICD 11 Status REF
Neuroendocrine cancer 2B72.1 Phase 2 [2]
Ovarian cancer 2C73 Phase 2 [2]
Indication(s) of JQ1
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
JQ1 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HUMAN bromodomain-containing protein 2 (BRD2) TTNISW6 BRD2_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Diffuse intrinsic pontine glioma DCU06XJ DIPG25 Investigative [1]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Uncovering the Role of BRD2 in COVID-19. 2020-03-19